Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

Posters will be made available on the Kineta website following presentations at the conference. KEYTRUDA ® is a registered trademark ... and a preclinical monoclonal antibody targeting CD27. For more ...

The posters were not created or installed by the city of New York, and photographs of them were actually from 2018. In October 2024, ahead of the U.S. presidential elections and as Republican ...

Poster figures should not be overly complicated, cluttered, or include too much information. Before sitting down to make their figures, scientists should first identify key pieces of information that ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell ... a type of RNA in cells that carry genetic information to create proteins ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

See additional selected KEYTRUDA indications in the U.S. after the Selected Important Safety Information. Selected Important Safety Information for KEYTRUDA Severe and Fatal Immune-Mediated Adverse ...

TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line ...